
PLx Pharma PLXP
Quartalsbericht 2022-Q3
hinzugefügt 16.05.2026
PLx Pharma Zahlungsmittel 2011-2026 | PLXP
Zahlungsmittel Jährlich PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 69.4 M | 22.4 M | 14 M | 14.3 M | 24.4 M | 59.3 K | 91.7 K | 27 M | 3.86 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 69.4 M | 59.3 K | 19.5 M |
Zahlungsmittel Vierteljährlich PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 25.8 M | 35.7 M | 52.5 M | 69.4 M | 82.6 M | 80.2 M | 84.4 M | 22.4 M | 9.09 M | 13.3 M | 9.29 M | 14 M | 18.5 M | 21.3 M | 24.3 M | 14.3 M | 16.5 M | 17.9 M | 20.4 M | 24.4 M | 30.4 M | 25.1 M | 12.4 M | 59.3 K | 7.84 M | 7.59 M | 4.17 M | 91.7 K | 9.19 M | 28.7 M | 24 M | 27 M | 29.9 M | 32.6 M | 36.1 M | 3.86 M | 3.86 M | 3.86 M | 3.86 M | 1.46 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 84.4 M | 59.3 K | 23.7 M |
Zahlungsmittel anderer Aktien in der Arzneimittelhersteller
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
13.6 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
974 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
11 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
11.4 M | $ 5.77 | -1.7 % | $ 85.7 M | ||
|
Cronos Group
CRON
|
792 M | $ 2.73 | -0.36 % | $ 1.05 B | ||
|
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
72.9 M | $ 34.17 | 3.55 % | $ 1.26 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
1.31 B | $ 5.4 | -1.28 % | $ 2 B | ||
|
Organogenesis Holdings
ORGO
|
93.7 M | $ 2.66 | - | $ 337 M | ||
|
Pacira BioSciences
PCRX
|
277 M | $ 24.36 | 4.33 % | $ 1.13 B | ||
|
Canopy Growth Corporation
CGC
|
114 M | $ 1.05 | 0.96 % | $ 113 M | ||
|
Solid Biosciences
SLDB
|
59.9 M | $ 6.88 | 3.93 % | $ 602 M | ||
|
Aurora Cannabis
ACB
|
138 M | $ 3.46 | - | $ 190 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 1.06 | -3.64 % | $ 1.32 M | ||
|
Jupiter Wellness
JUPW
|
2.28 M | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
207 M | $ 5.45 | 3.02 % | $ 3.37 B | ||
|
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
107 M | $ 1.11 | -0.89 % | $ 106 M | ||
|
Evolus
EOLS
|
53.8 M | $ 6.25 | 2.63 % | $ 403 M | ||
|
Sundial Growers
SNDL
|
252 M | $ 1.44 | -0.69 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
205 M | $ 9.13 | 8.05 % | $ 488 M | ||
|
Veru
VERU
|
15.8 M | $ 2.31 | -1.7 % | $ 33.8 M | ||
|
Neoleukin Therapeutics
NLTX
|
104 M | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
10.2 M | $ 23.46 | 0.09 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
2.26 M | $ 0.76 | -0.12 % | $ 3.06 M | ||
|
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
3.5 M | $ 7.17 | 1.85 % | $ 283 M | ||
|
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
21.3 M | $ 0.68 | -6.88 % | $ 34 M | ||
|
Viatris
VTRS
|
1.32 B | $ 16.26 | -2.34 % | $ 18.9 B | ||
|
Zomedica Corp.
ZOM
|
9.02 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
10.7 M | $ 0.76 | -4.74 % | $ 27.3 M | ||
|
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
345 K | $ 0.78 | 2.67 % | $ 3.35 M | ||
|
TherapeuticsMD
TXMD
|
7.48 M | $ 2.11 | -0.47 % | $ 24.4 M |